<DOC>
	<DOCNO>NCT01596712</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics immunogenicity QGE031 Japanese atopic male subject order determine eligibility Japanese patient subsequent clinical study .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Immunogenicity QGE031 Japanese Atopic Male Subjects</brief_title>
	<detailed_description />
	<criteria>Male Japanese subject atopic determine vitro test ( CAPRAST MAST test ) Serum IgE level must equal great 30 IU/mL screening . Poorly control asthma i.e . symptom asthma ( daytime nighttime ) use shortacting beta agonist relief asthma ( except exercise ) week Worsening asthma sign symptom prompt medical intervention within 1 year prior dose Severe atopic dermatitis within 1 year prior dosing , define history eruption severe inflammation erythema , papule , erosion , infiltration lichen Severe allergic rhinitis strongly disturb daily life within 1 year prior dose Severe allergic conjunctivitis ( e.g. , episodes giant papillary , limbal proliferation , shield ulcer ) within 1 year prior dose Prior use XolairÂ® antiIgE antibody Concomitant use allergy vaccination therapy Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Allergy ,</keyword>
	<keyword>Asthma ,</keyword>
	<keyword>Atopic dermatitis ,</keyword>
	<keyword>Japanese ,</keyword>
	<keyword>QGE031 ,</keyword>
	<keyword>IgE</keyword>
</DOC>